TPG Life Sciences Innovations led a $120m Series A round in Ouro Medicines.

TPG Life Sciences Innovations, a fund within TPG Capital, focused on investing in early-stage life sciences companies, led a $120m Series A round in Ouro Medicines, a biotechnology company, with participation from Monograph Capital, GSK, UPMC Enterprises, Boyu/Zoo Capital, and LongRiver Investments. "TPG has been following the theme of deep B cell depletion since initial data came from CAR-T cell therapies. In Ouro, we found a leadership team and a group of advisors who bring deep knowledge of immune-mediated diseases and the key modalities being investigated for these indications, as well as a wealth of experience in both drug discovery and clinical development. We are thrilled to support the company as it works to develop immune reset therapeutics that address serious unmet needs for patients," Shinichiro Fuse, TPG Life Sciences Innovations Business Unit Partner.